stockrow
Saturday 7 November 2026
Export AMIX’s income statement to Excel — free account
Autonomix Medical, Inc.
AMIX Healthcare Medical Devices
- EPS
- +77.7%
- Free cash flow
- −36.1%
Quarter to June 2026, against a year earlier
1.51
0.01
−0.66%
Follow AMIX
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM Jun ’26 | Trend | 10 yrs | 2027e | 2028e | 2029e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | — | — | 2 | 2 | 2 | 0.0% | |
| Gross margin, % | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
| EBT | — | — | — | — | — | (1) | (3) | (15) | (11) | (17) | (16) | +135.4% | ||||||
| EBT margin, % | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| Net income | — | — | — | — | — | (1) | (10) | (15) | (11) | (17) | (16) | +88.2% | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | |||||
| Earnings | — | — | — | — | — | — | (69.54) | (311.40) | (135.71) | (48.74) | (46.48) | (11.2%) | ||||||
| Cash flow | — | — | — | — | — | 0.00 | (0.23) | (134.30) | (98.19) | (35.76) | (24.32) | n/m | ||||||
| Capex | — | — | — | — | — | 0.00 | 0.00 | (0.38) | (0.17) | (0.03) | 0.00 | n/m | ||||||
| Free cash flow | — | — | — | — | — | 0.00 | (0.23) | (134.69) | (98.36) | (35.78) | (24.32) | n/m | ||||||
| Book value | — | — | — | — | — | 0.00 | (0.29) | 154.10 | 96.30 | 17.16 | 5.82 | n/m | ||||||
| Shares, m | — | — | — | — | — | — | 19 | 0 | 0 | 0 | 0 | (73.9%) | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | 0 | — | |||||
| P/S | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| P/B | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | — | (1) | (4) | (7) | (8) | (12) | (13) | +77.6% | |||||
| Capex | — | — | — | — | — | 0 | 0 | 0 | 0 | 0 | 0 | n/m | ||||||
| Free cash flow | — | — | — | — | — | (1) | (4) | (7) | (8) | (12) | (13) | +77.7% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | — | — | — | — | 1 | 9 | 8 | 6 | 3 | +102.1% | |||||
| Net debt | — | — | — | — | — | — | 0 | (8) | (9) | (7) | (3) | n/m | ||||||
| Shareholders’ equity | — | — | — | — | — | — | (6) | 8 | 8 | 6 | 3 | n/m | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | — | — | — | 0.00 | (232.83) | (275.07) | (118.77) | (192.06) | (248.22) | (192.1) pt | |||||
| ROIC | — | — | — | — | — | 0.00 | 0.00 | (34,176.14) | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| ROE | — | — | — | — | — | 0.00 | 125.75 | (1,517.56) | (145.10) | (238.89) | (315.99) | (238.9) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | — | — | — | — | 8 | 11 | 8 | — | 0.0% | |||||
| Revenue/emp, $m | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fundamentals updated 26 Oct 2026
Autonomix Medical, Inc. vs peers in Medical Devices (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| XAIR Beyond Air, Inc. | $3.6M | — (loss-making) | — (loss-making) | +0.45% (above 0%: growing) | n/m | −9.10% (below 0%: shrinking) | 12.73% | (373.98%) | Compare |
| VVOS Vivos Therapeutics, Inc. | $3.5M | — (loss-making) | — (loss-making) | +34.90% (above 0%: growing) | n/m | +16.44% (above 0%: growing) | 57.31% | (93.63%) | Compare |
| AMIX Autonomix Medical, Inc. | $3.0M | — (loss-making) | — | — | n/m | −36.10% (below 0%: shrinking) | — | 0.00% | |
| NUWE Nuwellis, Inc. | $2.5M | — (loss-making) | — (loss-making) | +14.14% (above 0%: growing) | n/m | −51.55% (below 0%: shrinking) | 76.08% | (160.94%) | Compare |
| AIDX 20/20 Biolabs Inc. | $2.5M | — (loss-making) | — (loss-making) | — | n/m | −23.98% (below 0%: shrinking) | 41.71% | (170.30%) | Compare |
| BJDX Bluejay Diagnostics, Inc. | $2.5M | — (loss-making) | — (loss-making) | — | n/m | +20.05% (above 0%: growing) | 0.00% | 0.00% | Compare |
| IVF INVO Fertility, Inc | $2.4M | — (loss-making) | — (loss-making) | +16.73% (above 0%: growing) | n/m | +35.07% (above 0%: growing) | 35.06% | (59.28%) | Compare |
| CODX Co-Diagnostics, Inc. | $2.4M | — (loss-making) | — (loss-making) | +1.96% (above 0%: growing) | n/m | +17.47% (above 0%: growing) | 72.73% | (3,733.17%) | Compare |
| ICCM IceCure Medical Ltd. | $2.4M | — (loss-making) | — (loss-making) | −0.69% (below 0%: shrinking) | n/m | +3.88% (above 0%: growing) | 32.38% | (466.19%) | Compare |
| Median of peers | $2.5M | — | — | +8.05% | — | +10.16% | 38.39% | (165.62%) |
Pay and ownership Proxy statement filed 14 September 2026
Ownership
Directors and executive officers, together
5.50%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement